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Tumor cells display progressive changes in metabo-
lism that correlate with malignancy, including devel-
opment of a lipogenic phenotype. How stored fats
are liberated and remodeled to support cancer
pathogenesis, however, remains unknown. Here,
we show that the enzyme monoacylglycerol lipase
(MAGL) is highly expressed in aggressive human
cancer cells and primary tumors, where it regulates
a fatty acid network enriched in oncogenic signaling
lipids that promotes migration, invasion, survival,
and in vivo tumor growth. Overexpression of MAGL
in nonaggressive cancer cells recapitulates this fatty
acid network and increases their pathogenicity—
phenotypes that are reversed by an MAGL inhibitor.
Impairments in MAGL-dependent tumor growth are
rescued by a high-fat diet, indicating that exogenous
sources of fatty acids can contribute to malignancy in
cancers lacking MAGL activity. Together, these find-
ings reveal how cancer cells can co-opt a lipolytic
enzyme to translate their lipogenic state into an array
of protumorigenic signals.
INTRODUCTION
The conversion of cells from a normal to cancerous state is
accompanied by reprogramming of metabolic pathways (Deber-
ardinis et al., 2008b; Jones and Thompson, 2009; Kroemer and
Pouyssegur, 2008), including those that regulate glycolysis
(Christofk et al., 2008; Gatenby and Gillies, 2004), glutamine-
dependent anaplerosis (DeBerardinis et al., 2007, 2008a;
Wise et al., 2008), and the production of lipids (DeBerardinis
et al., 2008a; Menendez and Lupu, 2007). Despite a growing
appreciation that dysregulated metabolism is a defining feature
of cancer, it remains unclear, in many instances, how such
biochemical changes occur and whether they play crucial rolesin disease progression and malignancy. Answers to these ques-
tions are important for identifying metabolic pathways that are
vital to the pathogenesis of cancer.
Among dysregulated metabolic pathways, heightened de
novo lipid biosynthesis, or the development of a ‘‘lipogenic’’
phenotype (Menendez and Lupu, 2007), has been posited to
play a major role in cancer. For instance, elevated levels of fatty
acid synthase (FAS), the enzyme responsible for fatty acid
biosynthesis from acetate and malonyl CoA, are correlated
with poor prognosis in breast cancer patients, and inhibition of
FAS results in decreased cell proliferation, loss of cell viability,
and decreased tumor growth in vivo (Kuhajda et al., 2000;
Menendez and Lupu, 2007; Zhou et al., 2007). FAS may support
cancer growth, at least in part, by providing metabolic substrates
for energy production (via fatty acid oxidation) (Buzzai et al.,
2005, 2007; Liu, 2006). Many other features of lipid biochemistry,
however, are also critical for supporting the malignancy of
cancer cells, including (1) the generation of building blocks for
newly synthesized membranes to accommodate high rates of
proliferation (DeBerardinis et al., 2008a, 2008b), (2) the composi-
tion and regulation of membrane structures that coordinate
signal transduction and motility (e.g., lipid rafts [Gao and Zhang,
2008], invadopodia [Stylli et al., 2008], blebs [Fackler and
Grosse, 2008]), and (3) the biosynthesis of an array of protumori-
genic lipid-signaling molecules. Prominent examples of lipid
messengers that contribute to cancer include (1) phosphatidyli-
nositol-3,4,5-trisphosphate [PI(3,4,5)P3], which is formed by
the action of phosphatidylinositol-3-kinase and activates protein
kinase B/Akt to promote cell proliferation and survival (Yuan and
Cantley, 2008; Zunder et al., 2008); (2) lysophosphatidic acid
(LPA), which signals through a family of G protein-coupled
receptors to stimulate cancer aggressiveness (Mills and Moole-
naar, 2003; Ren et al., 2006); and (3) prostaglandins formed by
cyclooxygenases, which support migration and tumor-host
interactions (Gupta et al., 2007; Marnett, 1992).
Lipogenesis may thus contribute to cancer by multiple mech-
anisms. Considering, however, that newly synthesized fatty
acids are rapidly incorporated into neutral- and phospho-lipid
stores (Menendez and Lupu, 2007), each of the aforementioned
models necessitates that cancer cells also possess aCell 140, 49–61, January 8, 2010 ª2010 Elsevier Inc. 49
complementary ‘‘lipolytic’’ pathway to liberate stored fatty acids
for metabolic and signaling purposes (Prentki and Madiraju,
2008; Przybytkowski et al., 2007).
Here, we use functional proteomic methods to discover a lipo-
lytic enzyme, monoacylglycerol lipase (MAGL), that is highly
elevated in aggressive cancer cells from multiple tissues of
origin. We show that MAGL, through hydrolysis of monoacylgly-
cerols (MAGs), controls free fatty acid (FFA) levels in cancer cells.
The resulting MAGL-FFA pathway feeds into a diverse lipid
network enriched in protumorigenic signaling molecules and
promotes migration, survival, and in vivo tumor growth. Aggres-
sive cancer cells thus pair lipogenesis with high lipolytic activity
to generate an array of protumorigenic signals that support their
malignant behavior.
RESULTS
Activity-Based Proteomic Analysis of Hydrolytic
Enzymes in Human Cancer Cells
To identify enzyme activities that contribute to cancer pathogen-
esis, we conducted a functional proteomic analysis of a panel of
aggressive and nonaggressive human cancer cell lines from
multiple tumors of origin, including melanoma (aggressive
[C8161, MUM2B], nonaggressive [MUM2C]), ovarian (aggres-
sive [SKOV3], nonaggressive [OVCAR3]), and breast (aggressive
[231MFP], nonaggressive [MCF7]) cancer. Aggressive cancer
lines were confirmed to display much greater in vitro migration
and in vivo tumor-growth rates compared to their nonaggressive
counterparts (Figure S1 available online), as previously shown
(Jessani et al., 2002, 2004; Seftor et al., 2002; Welch et al.,
1991). Proteomes from these cancer lines were screened by
activity-based protein profiling (ABPP) using serine hydrolase-
directed fluorophosphonate (FP) activity-based probes (Jessani
et al., 2002; Patricelli et al., 2001). Serine hydrolases are one of
the largest and most diverse enzyme classes in the human pro-
teome (representing 1%–1.5% of all human proteins) and play
important roles in many biochemical processes of potential
relevance to cancer, such as proteolysis (McMahon and Kwaan,
2008; Puustinen et al., 2009), signal transduction (Puustinen
et al., 2009), and lipid metabolism (Menendez and Lupu, 2007;
Zechner et al., 2005). The goal of this study was to identify hydro-
lytic enzyme activities that were consistently altered in aggres-
sive versus nonaggressive cancer lines, working under the
hypothesis that these conserved enzymatic changes would
have a high probability of contributing to the pathogenic state
of cancer cells.
Serine hydrolase activities were identified from aggressive and
nonaggressive cancer cell proteomes by enrichment with a bioti-
nylated FP probe (Liu et al., 1999) and multidimensional liquid
chromatography-mass spectrometry analysis (Jessani et al.,
2005). Among the more than 50 serine hydrolases detected in
this analysis (Tables S1, S2, and S3), two enzymes, KIAA1363
and MAGL, were found to be consistently elevated in aggressive
cancer cells relative to their nonaggressive counterparts, as
judged by spectral counting (Jessani et al., 2005; Liu et al.,
2004). We confirmed elevations in KIAA1363 and MAGL in
aggressive cancer cells by gel-based ABPP, where proteomes
are treated with a rhodamine-tagged FP probe and resolved by50 Cell 140, 49–61, January 8, 2010 ª2010 Elsevier Inc.1D-SDS-PAGE and in-gel fluorescence scanning (Figure 1A). In
both cases, two forms of each enzyme were detected (Fig-
ure 1A), due to differential glycoslyation for KIAA1363 (Jessani
et al., 2002), and possibly alternative splicing for MAGL (Karlsson
et al., 2001). We have previously shown that KIAA1363 plays
a role in regulating ether lipid signaling pathways in aggressive
cancer cells (Chiang et al., 2006). On the other hand, very little
was known about the function of MAGL in cancer.
The heightened activity of MAGL in aggressive cancer cells
was confirmed using the substrate C20:4 MAG (Figure 1B). Since
several enzymes have been shown to display MAG hydrolytic
activity (Blankman et al., 2007), we confirmed the contribution
that MAGL makes to this process in cancer cells using the potent
and selective MAGL inhibitor JZL184 (Long et al., 2009a).
JZL184 (1 mM, 4 hr) dramatically reduced the MAG hydrolytic
activity of cancer cells (Figure 1B) and selectively blocked the
FP-rhodamine signals for both the 33 and 35 kDa forms of
MAGL (Figure 1A). In contrast, JZL184 treatment did not alter
the hydrolytic activity displayed by cancer cells for several
additional classes of lipids, including diacylglycerols, triacylgly-
cerols, lysophospholipids, and phospholipids (Figure S1). These
data demonstrate that aggressive cancer cells display highly
elevated MAG hydrolytic activity and most, if not all, of this
activity originates from the MAGL enzyme.
MAGL Regulates Free Fatty Acid Levels in Aggressive
Cancer Cells
MAGL is perhaps best recognized for its role in degrading the
endogenous cannabinoid 2-arachidonoylglycerol (2-AG, C20:4
MAG), as well as other MAGs, in brain and peripheral tissues
(Dinh et al., 2002; Long et al., 2009a, 2009b; Nomura et al.,
2008). Consistent with this established function, blockade of
MAGL by JZL184 (1 mM, 4 hr) produced significant elevations
in the levels of several MAGs, including 2-AG, in each of the
aggressive cancer cell lines (Figure 1C and Figure S2). Interest-
ingly, however, MAGL inhibition also caused significant reduc-
tions in the levels of FFAs in aggressive cancer cells (Figure 1D
and Figure S2). This surprising finding contrasts with the function
of MAGL in normal tissues, where the enzyme does not, in
general, control the levels of FFAs (Long et al., 2009a, 2009b;
Nomura et al., 2008).
Curiously, we noted that, with the exception of C20:4 FFA
and MAG, the magnitude of reduction of FFAs greatly exceeded
the corresponding elevation in MAGs (5000–6100 pmol and
41–75 pmol, respectively, for C16:0, C18:0, and C18:1 lipids).
We hypothesized that this apparent discrepancy in mass
balance might be accounted for by the conversion of elevated
MAGs to alternative metabolites in JZL184-treated cancer cells.
Consistent with this premise, lipidomic analyses revealed signif-
icant increases in two major classes of lysophospholipids—lyso-
phosphatidyl choline (LPC) and lysophosphatidyl ethanolamine
(LPE)—in JZL184-treated cancer cells (Figure S1 and Table
S4). The cumulative magnitude of elevation of these lysophos-
pholipids (4100–6500 pmol) matched closely the reduction in
FFAs observed in JZL184-treated cells. Notably, we did not
detect C20:4 lysophospholipids in cancer cells, providing a likely
explanation for why JZL184 caused similar magnitudes of
elevation and reduction in C20:4 MAG and FFA, respectively.
Figure 1. MAGL Is Elevated in Aggressive Cancer Cells, where the Enzyme Regulates Monoacylglycerol and Free Fatty Acid Levels
(A) ABPP of serine hydrolase activities in nonaggressive (blue) and aggressive (red) human cancer cell lines. Serine hydrolase activities were labeled in whole-cell
proteomes with the activity-based probe FP-rhodamine and detected by SDS-PAGE and in-gel fluorescence scanning (fluorescent gel shown in grayscale). High-
lighted in red boxes are two enzymes, MAGL and KIAA1363 that are consistently elevated in aggressive versus nonaggressive cancer cells. Proteomes were also
prepared from cancer cells pretreated with DMSO or the selective MAGL inhibitor JZL184 (1 mM, 4 hr) to confirm that the 33 and 35 kDa FP-rhodamine-labeled
bands represented MAGL. See Table S1, Table S2, and Table S3 for a global analysis of FP-biotin-labeled serine hydrolase activities detected by ABPP in
cancer cells.
(B) C20:4 MAG hydrolytic activity of cancer cells in the presence (red bars) or absence (black bars) of JZL184 (1 mM, 4 hr).
(C and D) Inhibition of MAGL (JZL184 1 mM, 4 hr) raises MAG (C) and lowers FFA (D) levels in aggressive but not nonaggressive cells. See Table S4 for further
metabolite analysis of JZL184-treated cells. Note that aggressive cancer cells possess basally higher levels of FFAs (and lower levels of MAGs) compared
to nonaggressive cancer cells, reflecting their respective MAGL activities. *p < 0.05, **p < 0.01 for JZL184-treated versus DMSO-treated control groups.
#p < 0.05, ##p < 0.01 for aggressive versus nonaggressive cancer cells. Data are presented as means ± standard error of the mean (SEM); n = 4–5/group.Metabolic labeling studies using the non-natural C17:0-MAG
confirmed that MAGs are converted to LPC and LPE by aggres-
sive cancer cells, and that this metabolic transformation is signif-
icantly enhanced by treatment with JZL184 (Figure S1). Finally,
JZL184 treatment did not affect the levels of MAGs and FFAs
in nonaggressive cancer lines (Figures 1C and 1D), consistent
with the negligible expression of MAGL in these cells (Figures
1A and 1B).
We next stably knocked down MAGL expression by RNA
interference technology using two independent shRNA probes(shMAGL1, shMAGL2), both of which reduced MAGL activity
by 70%–80% in aggressive cancer lines (Figures 2A and 2D
and Figure S2). Other serine hydrolase activities were unaffected
by shMAGL probes (Figures 2A and 2D and Figure S2), confirm-
ing the specificity of these reagents. Both shMAGL probes
caused significant elevations in MAGs and corresponding reduc-
tions in FFAs in aggressive melanoma (Figures 2B and 2C),
ovarian (Figures 2E and 2F), and breast cancer cells (Figure S2).
Together, these data demonstrate that both acute (pharmaco-
logical) and stable (shRNA) blockade of MAGL cause elevationsCell 140, 49–61, January 8, 2010 ª2010 Elsevier Inc. 51
Figure 2. Stable shRNA-Mediated Knockdown of MAGL Lowers FFA Levels in Aggressive Cancer Cells
(A and D) MAGL was stably knocked down using two independent short-hairpin RNA (shRNA) oligonucleotides (shMAGL1, shMAGL2), resulting in >70% reduc-
tions in MAGL activity in C8161 and SKOV3 cells compared to shControl cells expressing an shRNA that targets a distinct serine hydrolase (DPPIV).
(B, C, E, and F) shMAGL cells show elevations in MAG (B and E) and reductions in FFA (C and F) levels. *p < 0.05, **p < 0.01 for shMAGL versus shControl groups.
#p < 0.05, ##p < 0.01 for aggressive versus nonaggressive cancer cells. The MAGL activity and MAG and FFA levels of shControl cells did not differ significantly
from those of parental cancer lines (shown in Figure 1). Data are presented as means ± SEM; n = 4–5/group. See also Table S4 and Figure S2.
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Figure 3. High-Grade Primary Human Ovarian Tumors Possess
Elevated MAGL Activity and FFAs Compared to Benign Tumors
(A) C20:4 MAG hydrolytic activity measurements for individual tumor speci-
mens. Pretreatment with JZL184 (1 mM, 30 min) confirmed that the majority
of the observed hydrolytic activity is due to MAGL.
(B) Summary graph of MAGL activity in benign versus high-grade tumors,
where each value is expressed as the JZL184-sensitive portion of total
C20:4 MAG hydrolytic activity shown in part (A).
(C) Levels of FFAs in benign versus high-grade tumors. **p < 0.01 for high-
grade versus benign tumor groups. Data are presented as means ± SEM;
n = 10–13/group.in MAGs and reductions in FFAs in aggressive cancer cells. It is
furthermore noteworthy that aggressive cancer cells were found
to express higher basal levels of FFAs (and conversely lower
levels of MAGs) than nonaggressive cancer cells (Figures 1C
and 1D), and this altered metabolic profile was largely eradicated
by MAGL inhibition. These intriguing findings indicate that MAGL
is the principal regulator of FFA levels in aggressive cancer cells.
Finally, we confirmed that MAGL activity (Figures 3A and 3B) and
FFA levels (Figure 3C) are also elevated in high-grade primary
human ovarian tumors compared to benign or low-grade tumors.
Thus, heightened expression of the MAGL-FFA pathway is
a prominent feature of both aggressive human cancer cell lines
and primary tumors.
Disruption of MAGL Expression and Activity Impairs
Cancer Pathogenicity
shMAGL cancer lines were next examined for alterations in path-
ogenicity using a set of in vitro and in vivo assays. shMAGL mela-
noma (C8161), ovarian (SKOV3), and breast (231MFP) cancer
cells exhibited significantly reduced in vitro migration (Figures
4A and 4F and Figure S2), invasion (Figures 4B and 4G and
Figure S2), and cell survival under serum-starvation conditions(Figures 4C and 4H and Figure S2). Acute pharmacological
blockade of MAGL by JZL184 also decreased cancer cell migra-
tion (Figure S2), but not survival, possibly indicating that maximal
impairments in cancer aggressiveness require sustained inhibi-
tion of MAGL.
shMAGL C8161 and SKOV3 cancer cells also exhibited
markedly reduced tumor growth rates in subcutaneous xeno-
graft transplantation studies performed in immune-deficient
mice (Figures 4D and 4I). Similar impairments in tumor growth
rates were observed in C8161 and SKOV3 xenograft-trans-
planted mice administered JZL184 once per day (40 mg/kg,
per os [p.o.]) (Figures 4E and 4J), a treatment regime that was
confirmed to block MAGL activity in tumors (Figure S3). Notably,
MAGL-disrupted tumors possessed lower FFA levels (Figure S3),
indicating that MAGL maintains its control over fatty acid metab-
olism in cancer cells grown in vivo.
Collectively, these in vitro and in vivo studies demonstrate that
MAGL activity supports several of the aggressive properties
exhibited by malignant cancer cells.
MAGL Overexpression Increases FFAs
and the Aggressiveness of Cancer Cells
We next asked whether expressing MAGL in nonaggressive
cancer cells might alter their lipid metabolic profiles and pathoge-
nicity. Stable MAGL-overexpressing (MAGL-OE) and control
(expressing an empty vector or a catalytically inactive version of
MAGL, where the serine nucleophile was mutated to alanine
[S122A]) variants of MUM2C and OVCAR3 cells were generated
by retroviral infection and evaluated by ABPP and C20:4 MAG
substrate assays for their respective MAGL activities. Both
assays confirmed that MAGL-OE cells possess greater than
10-fold elevations in MAGL activity compared to control cells
(Figure 5A and Figure S4). MAGL-OE cells also showed signifi-
cant reductions in MAGs (Figure 5B and Figure S4) and elevated
FFAs (Figure 5C and Figure S4). This altered metabolic profile was
accompanied by increased migration (Figure 5D and Figure S4),
invasion (Figure 5E and Figure S4), and survival (Figure S4) in
MAGL-OE cells. None of these effects were observed in cancer
cells expressing the S122A MAGL mutant, indicating that they
require MAGL activity. Also consistent with this premise, both
the metabolic and pathogenic effects observed in MAGL-OE cells
were reversed by a single treatment with JZL184 (1 mM, 4 hr)
(Figure 5 and Figure S4). Finally, MAGL-OE MUM2C cells also
showed enhanced tumor growth in vivo compared to control cells
(Figure 5F). Notably, the increased tumor growth rate of MAGL-
OE MUM2C cells nearly matched that of aggressive C8161 cells
(Figure S4), indicating that MAGL is sufficient to induce a highly
tumorigenic phenotype in melanoma cells. Collectively, these
data indicate that ectopic expression of MAGL in nonaggressive
cancer cells elevates their FFA levels and promotes pathogenicity
both in vitro and in vivo.
Metabolic Rescue of Impaired Pathogenicity
in MAGL-Disrupted Cancer Cells
MAGL could support the aggressiveness of cancer cells by
reducing the levels of its MAG substrates, elevating the levels
of its FFA products, or both. Among MAGs, the principal sig-
naling molecule is the endocannabinoid 2-AG, which activatesCell 140, 49–61, January 8, 2010 ª2010 Elsevier Inc. 53
Figure 4. shRNA-Mediated Knockdown and Pharmacological Inhibition of MAGL Impair Cancer Aggressiveness
(A–C and F–H) shMAGL cells show decreased migration (A and F), invasion (B and G), and cell survival (C and H) compared to shControl and uninfected parental
cells. Migration and invasion assays were performed by transferring cancer cells to serum-free media for 4 hr prior to seeding 50,000 cells into inserts with 8 mm
pore size containing membranes coated with collagen (10 mg/ml) or BioCoat Matrigel, respectively. C8161 and SKOV3 migration times were 5 hr and 20 hr,
respectively. Migrated or invaded cells refer to average numbers ± SEM per four fields counted at 4003 magnification. Cell survival assays were performed
by seeding 20,000 cells into 96 well plates in serum-free media. Survival was assessed using the WST-1 proliferation assay. Representative migration plates
(at 4003 magnification) are shown for shControl versus shMAGL cells (A and F).
(D and I) shMAGL cells show impaired tumor growth in SCID mice compared to shControl and uninfected parental cells. 2 3 106 C8161 or SKOV3 cells/100 ml
were injected subcutaneously into the flank and tumor growth was measured using calipers.
(E and J) JZL184 treatment (40 mg/kg daily oral administration in 4 ml/g polyethylene glycol 300 vehicle) significantly decreases tumor xenograft growth rates in
SCID mice compared to vehicle treatment. *p < 0.05, **p < 0.01 for shMAGL versus shControl or JZL184 versus vehicle treatment groups. shControl and parental
cancer cells did not differ significantly in their migration, cell survival, invasion, or in vivo tumor growth. Data are presented as means ±SEM; for (A)–(C) and (F)–(H),
n = 5–8/group; for (D), (E), (I), and (J), n = 6–11/group. See also Figure S3.the CB1 and CB2 receptors (Ahn et al., 2008; Mackie and Stella,
2006). The endocannabinoid system has been implicated previ-
ously in cancer progression and, depending on the specific
study, shown to promote (Sarnataro et al., 2006; Zhao et al.,
2005) or suppress (Endsley et al., 2007; Wang et al., 2008) cancer
pathogenesis. We therefore tested whether enhanced endocan-
nabinoid signaling (resulting from elevated levels of 2-AG)
might mediate the antimigratory effects observed in MAGL-
disrupted cancer cells. However, neither a CB1 nor CB2 antag-
onist rescued the migratory defects of shMAGL cancer cells
(Figure S5). CB1 and CB2 antagonists also did not affect the54 Cell 140, 49–61, January 8, 2010 ª2010 Elsevier Inc.levels of MAGs or FFAs in cancer cells (Figure S5). These find-
ings, combined with the low expression levels of CB1 and CB2
receptors in aggressive cancer cells (Figure S5), argue that
MAGL’s effects on cancer aggressiveness were not mediated
by endocannabinoid signaling.
Turning our attention to the products of MAGL-catalyzed reac-
tions, we reasoned that, if the protumorigenic effects of MAGL
were mediated by FFAs (or their secondary metabolites), then
the impaired pathogenicity of shMAGL cancer cells might be
rescued by treatment with exogenous sources of fatty acids.
In support of this premise, addition of palmitic or stearic acid
Figure 5. Ectopic Expression of MAGL Elevates FFA Levels and Enhances the In Vitro and In Vivo Pathogenicity of MUM2C Melanoma Cells
(A) MAGL overexpression (MAGL-OE, red bars) in MUM2C cells confirmed by ABPP (top panel), western blot (middle panel), and C20:4 MAG hydrolytic activity
(bottom panel). Control and S122A cells (black bars) correspond to cancer cells infected with empty vector (EV) or a catalytically inactive MAGL mutant (S122A),
respectively. Western analysis confirmed the overexpression of the S122A-MAGL mutant, which did not show any activity as judged by ABPP and C20:4 MAG
hydrolysis assays.
(B and C) MAGL-OE cells contain lower MAG (B) and higher FFA (C) levels compared to EV control and S122A cells. These metabolic effects were reversed by
in situ treatment with JZL184 (1 mM, 4 hr, maroon bars).
(D and E) MAGL-OE MUM2C cells show increased migration (D) and invasion (E) compared to EV and S122A control cells. This enhanced migration and invasion
was reversed by JZL184 (1 mM, 4 hr). Representative migration panels are shown (D).
(F) MAGL-OE MUM2C cells show a significantly enhanced tumor growth rate compared to EV or S122A control cells in SCID mice (orthotopically implanted
with 2 3 106 cells). *p < 0.05, **p < 0.01 for MAGL-OE versus control groups. Data are presented as means ± SEM; for (A)–(E), n = 4/group; for (F), n = 6/group.
See also Table S4 and Figure S4.(C16:0 and C18:0 FFAs, respectively; 20 mM, 4 hr), two principal
FFAs regulated by MAGL in aggressive cancer cells, to shMAGL
or JZL184-treated MAGL-OE cancer cells fully restored their
migratory activity (Figures 6A and 6B and Figure S2). C16:0
and C18:0 FFAs were also found to stimulate the migratory
activity of the nonaggressive cancer cells MUM2C and OVCAR3
(Figure 6B). We then determined whether increased FFA delivery
could rectify the tumor growth defect observed for shMAGL cells
in vivo. Immune-deficient mice were fed either a normal chow or
high-fat diet throughout the duration of a xenograft tumor
growth experiment. Notably, the impaired tumor growth rate of
shMAGL-C8161 cells was completely rescued in mice fed
a high-fat diet. In contrast, shControl-C8161 cells showed equiv-
alent tumor growth rates on a normal versus high-fat diet. The
recovery in tumor growth for shMAGL-C8161 cells in the high-
fat diet group correlated with significantly increased levels of
FFAs in excised tumors (Figure 6D).
Collectively, these results indicate that MAGL supports the
pathogenic properties of cancer cells by maintaining tonically
elevated levels of FFAs. We next asked whether this metabolic
profile might impact the larger lipid networks of aggressive
cancer cells.MAGL Regulates a Fatty Acid Network Enriched
in Protumorigenic Signals
We first considered whether the MAGL-FFA pathway might
serve as a means to regenerate NAD+ (via continual fatty acyl
glyceride/FFA recycling) to fuel glycolysis, which has been
hypothesized to explain a need for elevated neutral lipid hydro-
lase activity in cancers (Przybytkowski et al., 2007). Arguing
against this model, though, the NAD+/NADH ratios and pyruvate
and lactate levels were unaltered in shMAGL and MAGL-OE cells
relative to control cells (Figure S5). Another possible reason for
increased lipolysis could be to generate FFA substrates for
b-oxidation, which may serve as an important energy source
for cancer cells (Buzzai et al., 2005). However, inhibitors of carni-
tine palmitoyltransferase 1 (CPT1), which catalyzes the rate-
limiting step in b-oxidation (McGarry and Brown, 1997), did not
affect the migratory activity of cancer cells (shControl, shMAGL,
or MAGL-OE) (Figure S5). CPT1 blockade also failed to alter FFA
levels in cancer cells, with the exception of C20:4 FFA, which
was elevated only in shControl cells (Figure S5). Additional
studies revealed reduced expression of CPT1 in aggressive
cancer cells (data not shown), as has been reported previously
(Deberardinis et al., 2006), providing further evidence againstCell 140, 49–61, January 8, 2010 ª2010 Elsevier Inc. 55
Figure 6. Recovery of the Pathogenic Properties of shMAGL Cancer Cells by Treatment with Exogenous Fatty Acids
(A) The reduced migration of shMAGL cells is reversed by treatment with palmitic or stearic acid (20 mM, 4 hr, hatched red bars).
(B) Addition of palmitic or stearic acid (20 mM, 4 hr) increases the migration of MUM2C and OVCAR3 cells and rescues the reduced migration in JZL184-treated
MAGL-OE cells.
(C) The reduced tumor growth of shMAGL-C8161 cells is reversed by treatment with a high-fat diet (HFD) (60 kcal% fat). Mice were placed on normal chow (NC) or
HFD 2 weeks prior to flank injection of cancer cells and maintained on these diets throughout the tumor growth time course. Inset, body weights for animals
throughout time course.
(D) Explanted shMAGL tumors from the HFD group (hatched red bars) contain elevated FFA levels compared to shMAGL tumors from the NC group (red bars).
*p < 0.05, **p < 0.01 shMAGL versus shControl groups. ##p < 0.01 for palmitic or stearic acid- or HFD-treated shMAGL groups versus shMAGL control groups
(DMSO- and NC-treated groups, respectively). Data are presented as means ± SEM; For (A), n = 4–5/group; for (B) and (C), n = 7–8/group. See also Figure S5.a role for b-oxidation as a downstream mediator of the patho-
genic effects of the MAGL-fatty acid pathway.
Considering that FFAs are fundamental building blocks for the
production and remodeling of membrane structures and
signaling molecules, perturbations in MAGL might be expected
to affect several lipid-dependent biochemical networks impor-
tant for malignancy. To test this hypothesis, we performed
lipidomic analyses of cancer cell models with altered MAGL
activity, including comparisons of (1) MAGL-OE versus control
cancer cells (OVCAR3, MUM2C) and (2) shMAGL versus
shControl cancer cells (SKOV3, C8161). Organic extracts of
cancer cells were analyzed using an untargeted liquid chroma-
tography-mass spectrometry (LC-MS) platform that profiles
several major lipid families (Chiang et al., 2006; Saghatelian
et al., 2004), and metabolites with significantly altered levels
between the comparison groups were identified using the
XCMS software (Smith et al., 2006). Complementing these global
profiles, we also conducted targeted measurements of specific
bioactive lipids (e.g., prostaglandins) that are too low in abun-56 Cell 140, 49–61, January 8, 2010 ª2010 Elsevier Inc.dance for detection by standard lipidomic methods. The result-
ing data sets were then mined to identify a common signature
of lipid metabolites regulated by MAGL, which we defined as
metabolites that were significantly increased or reduced in
MAGL-OE cells and showed the opposite change in shMAGL
cells relative to their respective control groups (Figures 7A and
7B and Table S4).
Most of the lipids in the MAGL-fatty acid network, including
several lysophospholipids (LPC, LPA, LPE), ether lipids (MAGE,
alkyl LPE), phosphatidic acid (PA), and prostaglandin E2
(PGE2), displayed similar profiles to FFAs, being consistently
elevated and reduced in MAGL-OE and shMAGL cells, respec-
tively. Only MAGs were found to show the opposite profile
(elevated and reduced in shMAGL and MAGL-OE cells, respec-
tively). Interestingly, virtually this entire lipidomic signature was
also observed in aggressive cancer cells when compared to their
nonaggressive counterparts (e.g., C8161 versus MUM2C and
SKOV3 versus OVCAR3, respectively; Table S4). These findings
demonstrate that MAGL regulates a lipid network in aggressive
cancer cells that consists of not only FFAs and MAGs but also
a host of secondary lipid metabolites. We were further intrigued
to find that acute inhibition of MAGL by JZL184 produced
a distinct secondary lipidomic signature. As was observed in
shMAGL cells, JZL184 treatment caused reductions in LPA
and PGE2 in each of the cancer lines expressing high levels of
MAGL (Figures 7C and 7D and Table S4). In contrast, and as
noted earlier, increases (rather than decreases) in LPCs and
LPEs were observed in JZL184-treated cells (Figure S1 and
Table S4). These data indicate that acute and chronic blockade
of MAGL generate distinct metabolomic effects in cancer cells,
likely reflecting the differential outcomes of short- versus long-
term depletion of FFAs. Finally, several additional classes of
lipids, including phosphatidylcholines, phosphatidylethanol-
amines, ceramides, sphingosine-1-phosphate, cholesterol,
diacylglycerols, and triacylglycerols, were not affected by reduc-
tions or elevations in MAGL activity (Table S4), thus underscoring
the restricted composition of the fatty acid network regulated by
this enzyme.
Within the MAGL-fatty acid network are several protumori-
genic lipid messengers, including LPA and PGE2, that have
been shown to promote the aggressiveness of cancer cells
(Gupta et al., 2007; Mills and Moolenaar, 2003). Metabolic
labeling studies confirmed that aggressive cancer cells can
convert both MAGs and FFAs (Figure S1) to LPA and PGE2,
and for MAGs, this conversion was blocked by JZL184
(Figure S1). Interestingly, treatment with either LPA or PGE2
(100 nM, 4 hr) rescued the impaired migration of shMAGL cancer
cells at concentrations that did not affect the migration of shCon-
trol cells (Figure 7E). Conversely, the enhanced migratory activity
of MAGL-OE cancer cells was completely blocked by the Gi/Go
inhibitor pertussis toxin (Figure 7F). Finally, the degree of stimu-
lated migration observed in MAGL-OE cells equaled the maximal
effect produced by exogenous addition of LPA (Figure 7G).
Taken together, these data suggest that MAGL contributes
to cancer pathogenicity, at least in part, by elevating the produc-
tion of bioactive lipids that act on G protein-coupled receptors
to promote high migratory activity. To assess whether the
MAGL-fatty acid network interacts with other protumorigenic
signaling systems, we treated shMAGL and shControl cells
with an inhibitor of the epidermal growth factor receptor
(EGFR). shMAGL cells show significantly heightened sensitivity
to the antimigratory (Figure 7H and Figure S6) and antisurvival
(Figure S6) effects of EGFR blockade. These data are consistent
with previous findings indicating substantial crosstalk between
LPA and EGFR signaling pathways in cancer cells (Bektas
et al., 2005; Gschwind et al., 2002).
DISCUSSION
Heightened lipogenesis is an established early hallmark of dysre-
gulated metabolism and pathogenicity in cancer (Menendez and
Lupu, 2007). Cancer lipogenesis appears to be driven principally
by FAS, which is elevated in most transformed cells and
important for survival and proliferation (De Schrijver et al.,
2003; Kuhajda et al., 2000; Vazquez-Martin et al., 2008). It is
not yet clear how FAS supports cancer growth, but most of the
proposed mechanisms invoke protumorigenic functions for theenzyme’s fatty acid products and their lipid derivatives (Menen-
dez and Lupu, 2007). This creates a conundrum because the
fatty acid molecules produced by FAS are thought to be rapidly
incorporated into neutral and phospho-lipids, pointing to the
need for complementary lipolytic pathways in cancer cells to
release stored fatty acids for metabolic and signaling purposes
(Prentki and Madiraju, 2008; Przybytkowski et al., 2007). Consis-
tent with this hypothesis, we found that acute treatment with
the FAS inhibitor C75 (40 mM, 4 hr) did not reduce FFA levels
in cancer cells (data not shown). Furthermore, aggressive
and nonaggressive cancer cells exhibited similar levels of FAS
(data not shown), indicating that lipogenesis in the absence
of paired lipolysis may be insufficient to confer high levels of
malignancy.
Here we show that aggressive cancer cells do indeed acquire
the ability to liberate FFAs from neutral lipid stores as a conse-
quence of heightened expression of MAGL. MAGL and its FFA
products were found to be elevated in aggressive human cancer
cell lines from multiple tissues of origin, as well as in high-grade
primary human ovarian tumors. These data suggest that the
MAGL-FFA pathway may be a conserved feature of advanced
forms of many types of cancer. Further evidence in support of
this premise originates from gene expression profiling studies,
which have identified increased levels of MAGL in primary
human ductal breast tumors compared to less malignant medul-
lary breast tumors (Gjerstorff et al., 2006). The key role that
MAGL plays in regulating FFA levels in aggressive cancer cells
contrasts with the function of this enzyme in normal tissues,
where it mainly controls the levels of MAGs, but not FFAs
(Long et al., 2009b). These data thus provide a striking example
of the co-opting of an enzyme by cancer cells to serve a distinct
metabolic purpose that supports their pathogenic behavior.
We determined that MAGL is both necessary and sufficient to
elevate FFAs and confer high migratory and tumorigenic activity
in cancer cells. Blockade of MAGL impaired not only in vitro
migration but also in vivo tumor growth, and both phenotypes
were rescued by exogenous sources of FFAs. These data, in
combination with the lack of effect of cannabinoid receptor
antagonists on migration, indicate that the mechanism of
MAGL-stimulated cancer aggressiveness involves the action of
FFA-derived products, rather than reductions in MAGL sub-
strates, such as the endocannabinoid 2-AG. Additional studies
argued against a major role for b-oxidation or glycolysis in medi-
ating MAGL-dependent aggressiveness. Instead, we found that
MAGL regulates a host of secondary lipid metabolites that
include key signaling molecules, such as LPA and PGE2, known
to support cancer malignancy. Our finding that impairments in
the MAGL–FFA pathway can be rescued by exogenous fatty
acids, including a high-fat diet in vivo, has provocative implica-
tions for the crosstalk between obesity and tumorigenesis. It
has been postulated that excessive fat accumulation may exac-
erbate the development and progression of cancer (Calle and
Kaaks, 2004; Calle et al., 2003), and, conversely, reductions
in caloric intake have been shown to impede tumor growth
(Kalaany and Sabatini, 2009). Our data suggest one mechanism
whereby a high-fat diet might promote malignancy, namely, by
stimulating the growth and migratory activity of cancer cells
that do not themselves exhibit high rates of lipolysis.Cell 140, 49–61, January 8, 2010 ª2010 Elsevier Inc. 57
Figure 7. MAGL Regulates a Lipid Network Enriched in Protumorigenic Signaling Molecules
(A and B) Lipidomic analyses of cancer cell models with altered MAGL activity comparing MAGL-OE versus EV control (A) and shMAGL versus shControl (B) cells.
The metabolites shown are those that were increased (red) or decreased (blue) in MAGL-OE (both MUM2C and OVCAR3) versus EV control cells (A) and showed
the opposite profile in shMAGL (both C8161 and SKOV3) versus shControl cells (B). Parent masses of metabolites are provided, and the size of circles indicates
the relative magnitude of change. Quantitation of lipid levels are provided in Table S4.
(C and D) Quantitation of C16:0 LPA and PGE2 levels in cancer cell models.
(E) Treatment of shMAGL cancer cells with C16:0 LPA (100 nM, 4 hr) or PGE2 (100 nM, 4 hr) rescues their defective migration compared to shControl cells.
(F) Pertussis toxin (PTX) (100 ng/ml, 4 hr) reverses the increased migration of MAGL-OE cancer cells.
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Taken together, our results indicate that MAGL serves as key
metabolic hub in aggressive cancer cells, where the enzyme
regulates a fatty acid network that feeds into a number of protu-
morigenic signaling pathways. Additional studies will be required
to determine precisely how FFAs are converted to protumori-
genic lipid transmitters, although some obvious candidate
pathways can be schematized (Figure 7I). It will be interesting
to determine whether any of the enzymatic components of these
pathways are also dysregulated in pathogenic cancers. One
might also anticipate that cancer cells could exhibit heightened
levels of additional hydrolytic activities (e.g., di- and tri-acylgly-
cerol hydrolysis) to further capitalize on their lipogenic state,
although we should note that the aggressive cancer cells exam-
ined herein displayed much lower di- and tri-acylglycerol lipase
activity compared to MAGL activity, and these former activities
did not differ between aggressive and nonaggressive cancer
cells (Figure S1). Finally, considering that endocannabinoids
(Wang et al., 2008), b-oxidation (Buzzai et al., 2005; Liu, 2006),
and fatty acid-sustained glycolysis (Przybytkowski et al., 2007)
have each been described as potential contributing elements
to tumorigenesis, it is possible that these pathways may
prove relevant for MAGL-dependent aggressiveness in other
types of cancer. Independent of which of these mechanisms
is operational in specific cancers, our data suggest that they
would each function downstream of MAGL, thus designating
this enzyme as a potentially exciting pharmacological target for
future cancer therapy.
EXPERIMENTAL PROCEDURES
Pharmacological Inhibition of MAGL in Cancer Cells
Pharmacological inhibition studies were conducted as described previously
(Chiang et al., 2006). Cells were incubated in serum-free media with JZL184
(1 mM) or vehicle (DMSO) for 4 hr, after which the cells were harvested and
analyzed.
ABPP and Hydrolytic Activity Assays of Cancer Cell Proteomes
Identification and comparative quantitiation of serine hydrolase activities from
cancer cell proteomes by ABPP-MudPIT or gel-based ABPP were conducted
as previously described using FP-biotin (5 mM) and FP-rhodamine (2 mM),
respectively (Jessani et al., 2002, 2005). C20:4 MAG hydrolytic activity assays
were performed as described previously (Blankman et al., 2007).
RNA Interference Studies in Human Cancer Cell Lines
RNA interference studies were conducted as described previously (Chiang
et al., 2006). Short-hairpin RNA constructs were subcloned into the pLP-
RetroQ acceptor system, and retrovirus was generated by using the Ampho-
Pack-293 Cell Line (Clontech).(G) Concentration-dependent stimulation of migration by LPA in EV control ver
by LPA in EV control cells matches the basally enhanced migration observed in
OE cells.
(H) Sensitivity of shControl versus shMAGL cancer cells to the EGFR inhibitor tyrp
lute numbers of migrated cells and the effect of tyrphostin on cell survival are s
provided in the panels.
(I) Scheme showing a possible metabolic network connecting the MAGL-FFA pa
For (A) and (B), data are presented as mean relative changes between comparis
shMAGL versus respective control cell groups (C–G), JZL184-treated versus D
(MUM2C, OVCAR3) versus aggressive (C8161, SKOV3) cells (C and D), or LP
means ± SEM; n = 3–5/group.Overexpression Studies in Human Cancer Cell Lines
Stable MAGL overexpression was achieved by subcloning the MAGL gene into
the pMSCVpuro vector (Clontech), generating retrovirus using the Ampho-
Pack-293 Cell Lines.
Lipid Measurements in Cancer Cells
Lipid measurements were conducted similarly to protocols described previ-
ously (Chiang et al., 2006). Briefly, cell metabolomes were extracted with
2:1:1 chloroform:methanol:Tris buffer. The organic layer was extracted,
followed by acidification of the acqueous phase and re-extraction with chloro-
form. The organic phases were combined, dried under N2, and resuspended in
chloroform for LC-MS analysis.
Cell Migration, Cell Survival, Invasion, and Tumor Xenograft Studies
Migration, cell survival, invasion, and tumor xenograft studies of cancer cells
were performed as described in the Extended Experimental Procedures.
Migration assays were performed in Transwell chambers (Corning) coated
with 10 mg/ml collagen. Cell survival assays were performed using the Cell
Proliferation Reagent WST-1 (Roche). Invasion assays were conducted using
the BD Matrigel Invasion Chambers. Human cancer xenografts were estab-
lished by transplanting cancer cell lines ectopically into the flank of C.B17
SCID mice.
For more details on the methods, please see the Extended Experimental
Procedures available online.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
six figures, and four tables and can be found with this article online at
doi:10.1016/j.cell.2009.11.027.
ACKNOWLEDGMENTS
We thank the members of the Cravatt laboratory for helpful discussion and crit-
ical reading of the manuscript. In particular, we acknowledge Gabriel M. Simon
for assistance with data analysis, Michele K. McKinney, and Jacqueline
L. Blankman for technical assistance. This work was supported by the National
Institutes of Health (CA132630, CA087660) and the Skaggs Institute for Chem-
ical Biology.
Received: May 5, 2009
Revised: August 18, 2009
Accepted: November 4, 2009
Published: January 7, 2010
REFERENCES
Ahn, K., McKinney, M.K., and Cravatt, B.F. (2008). Enzymatic pathways that
regulate endocannabinoid signaling in the nervous system. Chem. Rev. 108,
1687–1707.
Bektas,M.,Payne,S.G.,Liu, H., Goparaju,S.,Milstien,S., andSpiegel, S. (2005).
A novel acylglycerol kinase that produces lysophosphatidic acid modulates
cross talk with EGFR in prostate cancer cells. J. Cell Biol. 169, 801–811.sus MAGL-OE cells. Note that the maximal stimulation of migration induced
MAGL-OE cells, and LPA does not further increase the migration of MAGL-
hostin AG-1478, expressed as percentage of migration impairment. The abso-
hown in Figure S6. IC50 values for the antimigratory effects of tyrphostin are
thway to other protumorigenic lipids.
on groups; n = 4–5/group. For (C)–(G), *p < 0.05, **p < 0.01 for MAGL-OE or
MSO-treated control cells (C and D). ##p < 0.01 for parental nonaggressive
A/PGE2-treated shMAGL versus shControl cells (E). Data are presented as
Cell 140, 49–61, January 8, 2010 ª2010 Elsevier Inc. 59
Blankman, J.L., Simon, G.M., and Cravatt, B.F. (2007). A comprehensive
profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoyl-
glycerol. Chem. Biol. 14, 1347–1356.
Buzzai, M., Bauer, D.E., Jones, R.G., Deberardinis, R.J., Hatzivassiliou, G.,
Elstrom, R.L., and Thompson, C.B. (2005). The glucose dependence of Akt-
transformed cells can be reversed by pharmacologic activation of fatty acid
beta-oxidation. Oncogene 24, 4165–4173.
Buzzai, M., Jones, R.G., Amaravadi, R.K., Lum, J.J., DeBerardinis, R.J., Zhao,
F., Viollet, B., and Thompson, C.B. (2007). Systemic treatment with the antidi-
abetic drug metformin selectively impairs p53-deficient tumor cell growth.
Cancer Res. 67, 6745–6752.
Calle, E.E., and Kaaks, R. (2004). Overweight, obesity and cancer: epidemio-
logical evidence and proposed mechanisms. Nat. Rev. Cancer 4, 579–591.
Calle, E.E., Rodriguez, C., Walker-Thurmond, K., and Thun, M.J. (2003). Over-
weight, obesity, and mortality from cancer in a prospectively studied cohort of
U.S. adults. N. Engl. J. Med. 348, 1625–1638.
Chiang, K.P., Niessen, S., Saghatelian, A., and Cravatt, B.F. (2006). An enzyme
that regulates ether lipid signaling pathways in cancer annotated by multidi-
mensional profiling. Chem. Biol. 13, 1041–1050.
Christofk, H.R., Vander Heiden, M.G., Harris, M.H., Ramanathan, A., Gerszten,
R.E., Wei, R., Fleming, M.D., Schreiber, S.L., and Cantley, L.C. (2008). The M2
splice isoform of pyruvate kinase is important for cancer metabolism and
tumour growth. Nature 452, 230–233.
De Schrijver, E., Brusselmans, K., Heyns, W., Verhoeven, G., and Swinnen,
J.V. (2003). RNA interference-mediated silencing of the fatty acid synthase
gene attenuates growth and induces morphological changes and apoptosis
of LNCaP prostate cancer cells. Cancer Res. 63, 3799–3804.
DeBerardinis, R.J., Lum, J.J., and Thompson, C.B. (2006). Phosphatidylinosi-
tol 3-kinase-dependent modulation of carnitine palmitoyltransferase 1A
expression regulates lipid metabolism during hematopoietic cell growth.
J. Biol. Chem. 281, 37372–37380.
DeBerardinis, R.J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S.,
and Thompson, C.B. (2007). Beyond aerobic glycolysis: transformed cells can
engage in glutamine metabolism that exceeds the requirement for protein and
nucleotide synthesis. Proc. Natl. Acad. Sci. USA 104, 19345–19350.
DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G., and Thompson, C.B. (2008a).
The biology of cancer: metabolic reprogramming fuels cell growth and prolif-
eration. Cell Metab. 7, 11–20.
Deberardinis, R.J., Sayed, N., Ditsworth, D., and Thompson, C.B. (2008b).
Brick by brick: metabolism and tumor cell growth. Curr. Opin. Genet. Dev.
18, 54–61.
Dinh, T.P., Freund, T.F., and Piomelli, D. (2002). A role for monoglyceride lipase
in 2-arachidonoylglycerol inactivation. Chem. Phys. Lipids 121, 149–158.
Endsley, M.P., Aggarwal, N., Isbell, M.A., Wheelock, C.E., Hammock, B.D.,
Falck, J.R., Campbell, W.B., and Nithipatikom, K. (2007). Diverse roles of
2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location,
hydrolysis and 12-lipoxygenase metabolism. Int. J. Cancer 121, 984–991.
Fackler, O.T., and Grosse, R. (2008). Cell motility through plasma membrane
blebbing. J. Cell Biol. 181, 879–884.
Gao, X., and Zhang, J. (2008). Spatiotemporal analysis of differential Akt regu-
lation in plasma membrane microdomains. Mol. Biol. Cell 19, 4366–4373.
Gatenby, R.A., and Gillies, R.J. (2004). Why do cancers have high aerobic
glycolysis? Nat. Rev. Cancer 4, 891–899.
Gjerstorff, M.F., Benoit, V.M., Laenkholm, A.V., Nielsen, O., Johansen, L.E.,
and Ditzel, H.J. (2006). Identification of genes with altered expression in
medullary breast cancer vs. ductal breast cancer and normal breast epithelia.
Int. J. Oncol. 28, 1327–1335.
Gschwind, A., Prenzel, N., and Ullrich, A. (2002). Lysophosphatidic acid-
induced squamous cell carcinoma cell proliferation and motility involves
epidermal growth factor receptor signal transactivation. Cancer Res. 62,
6329–6336.
Gupta, G.P., Nguyen, D.X., Chiang, A.C., Bos, P.D., Kim, J.Y., Nadal, C.,
Gomis, R.R., Manova-Todorova, K., and Massague, J. (2007). Mediators of60 Cell 140, 49–61, January 8, 2010 ª2010 Elsevier Inc.vascular remodelling co-opted for sequential steps in lung metastasis. Nature
446, 765–770.
Jessani, N., Liu, Y., Humphrey, M., and Cravatt, B.F. (2002). Enzyme activity
profiles of the secreted and membrane proteome that depict cancer cell
invasiveness. Proc. Natl. Acad. Sci. USA 99, 10335–10340.
Jessani, N., Humphrey, M., McDonald, W.H., Niessen, S., Masuda, K.,
Gangadharan, B., Yates, J.R., 3rd, Mueller, B.M., and Cravatt, B.F. (2004).
Carcinoma and stromal enzyme activity profiles associated with breast tumor
growth in vivo. Proc. Natl. Acad. Sci. USA 101, 13756–13761.
Jessani, N., Niessen, S., Wei, B.Q., Nicolau, M., Humphrey, M., Ji, Y., Han, W.,
Noh, D.Y., Yates, J.R., 3rd, Jeffrey, S.S., et al. (2005). A streamlined platform
for high-content functional proteomics of primary human specimens. Nat.
Methods 2, 691–697.
Jones, R.G., and Thompson, C.B. (2009). Tumor suppressors and cell metab-
olism: a recipe for cancer growth. Genes Dev. 23, 537–548.
Kalaany, N.Y., and Sabatini, D.M. (2009). Tumours with PI3K activation are
resistant to dietary restriction. Nature 458, 725–731.
Karlsson, M., Reue, K., Xia, Y.R., Lusis, A.J., Langin, D., Tornqvist, H., and
Holm, C. (2001). Exon-intron organization and chromosomal localization of
the mouse monoglyceride lipase gene. Gene 272, 11–18.
Kroemer, G., and Pouyssegur, J. (2008). Tumor cell metabolism: cancer’s
Achilles’ heel. Cancer Cell 13, 472–482.
Kuhajda, F.P., Pizer, E.S., Li, J.N., Mani, N.S., Frehywot, G.L., and Townsend,
C.A. (2000). Synthesis and antitumor activity of an inhibitor of fatty acid
synthase. Proc. Natl. Acad. Sci. USA 97, 3450–3454.
Liu, H., Sadygov, R.G., and Yates, J.R., 3rd. (2004). A model for random
sampling and estimation of relative protein abundance in shotgun proteomics.
Anal. Chem. 76, 4193–4201.
Liu, Y. (2006). Fatty acid oxidation is a dominant bioenergetic pathway in
prostate cancer. Prostate Cancer Prostatic Dis. 9, 230–234.
Liu, Y., Patricelli, M.P., and Cravatt, B.F. (1999). Activity-based protein
profiling: the serine hydrolases. Proc. Natl. Acad. Sci. USA 96, 14694–14699.
Long, J.Z., Li, W., Booker, L., Burston, J.J., Kinsey, S.G., Schlosburg, J.E.,
Pavon, F.J., Serrano, A.M., Selley, D.E., Parsons, L.H., et al. (2009a). Selective
blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behav-
ioral effects. Nat. Chem. Biol. 5, 37–44.
Long, J.Z., Nomura, D.K., and Cravatt, B.F. (2009b). Characterization of mono-
acylglycerol lipase inhibition reveals differences in central and peripheral
endocannabinoid metabolism. Chem. Biol. 16, 744–753.
Mackie, K., and Stella, N. (2006). Cannabinoid receptors and endocannabi-
noids: evidence for new players. AAPS J. 8, E298–E306.
Marnett, L.J. (1992). Aspirin and the potential role of prostaglandins in colon
cancer. Cancer Res. 52, 5575–5589.
McGarry, J.D., and Brown, N.F. (1997). The mitochondrial carnitine palmitoyl-
transferase system. From concept to molecular analysis. Eur. J. Biochem. 244,
1–14.
McMahon, B., and Kwaan, H.C. (2008). The plasminogen activator system and
cancer. Pathophysiol. Haemost. Thromb. 36, 184–194.
Menendez, J.A., and Lupu, R. (2007). Fatty acid synthase and the lipogenic
phenotype in cancer pathogenesis. Nat. Rev. Cancer 7, 763–777.
Mills, G.B., and Moolenaar, W.H. (2003). The emerging role of lysophosphati-
dic acid in cancer. Nat. Rev. Cancer 3, 582–591.
Nomura, D.K., Blankman, J.L., Simon, G.M., Fujioka, K., Issa, R.S., Ward,
A.M., Cravatt, B.F., and Casida, J.E. (2008). Activation of the endocannabinoid
system by organophosphorus nerve agents. Nat. Chem. Biol. 4, 373–378.
Patricelli, M.P., Giang, D.K., Stamp, L.M., and Burbaum, J.J. (2001). Direct
visualization of serine hydrolase activities in complex proteomes using fluores-
cent active site-directed probes. Proteomics 1, 1067–1071.
Prentki, M., and Madiraju, S.R. (2008). Glycerolipid metabolism and signaling
in health and disease. Endocr. Rev. 29, 647–676.
Przybytkowski, E., Joly, E., Nolan, C.J., Hardy, S., Francoeur, A.M., Langelier,
Y., and Prentki, M. (2007). Upregulation of cellular triacylglycerol - free fatty
acid cycling by oleate is associated with long-term serum-free survival of
human breast cancer cells. Biochem. Cell Biol. 85, 301–310.
Puustinen, P., Junttila, M.R., Vanhatupa, S., Sablina, A.A., Hector, M.E.,
Teittinen, K., Raheem, O., Ketola, K., Lin, S., Kast, J., et al. (2009). PME-1
protects extracellular signal-regulated kinase pathway activity from protein
phosphatase 2A-mediated inactivation in human malignant glioma. Cancer
Res. 69, 2870–2877.
Ren, J., Xiao, Y.J., Singh, L.S., Zhao, X., Zhao, Z., Feng, L., Rose, T.M.,
Prestwich, G.D., and Xu, Y. (2006). Lysophosphatidic acid is constitutively
produced by human peritoneal mesothelial cells and enhances adhesion,
migration, and invasion of ovarian cancer cells. Cancer Res. 66, 3006–3014.
Saghatelian, A., Trauger, S.A., Want, E.J., Hawkins, E.G., Siuzdak, G., and
Cravatt, B.F. (2004). Assignment of endogenous substrates to enzymes by
global metabolite profiling. Biochemistry 43, 14332–14339.
Sarnataro, D., Pisanti, S., Santoro, A., Gazzerro, P., Malfitano, A.M., Laezza,
C., and Bifulco, M. (2006). The cannabinoid CB1 receptor antagonist rimona-
bant (SR141716) inhibits human breast cancer cell proliferation through a lipid
raft-mediated mechanism. Mol. Pharmacol. 70, 1298–1306.
Seftor, E.A., Meltzer, P.S., Kirschmann, D.A., Pe’er, J., Maniotis, A.J., Trent,
J.M., Folberg, R., and Hendrix, M.J. (2002). Molecular determinants of human
uveal melanoma invasion and metastasis. Clin. Exp. Metastasis 19, 233–246.
Smith, C.A., Want, E.J., O’Maille, G., Abagyan, R., and Siuzdak, G. (2006).
XCMS: processing mass spectrometry data for metabolite profiling using
nonlinear peak alignment, matching, and identification. Anal. Chem. 78,
779–787.
Stylli, S.S., Kaye, A.H., and Lock, P. (2008). Invadopodia: at the cutting edge of
tumour invasion. J. Clin. Neurosci. 15, 725–737.
Vazquez-Martin, A., Colomer, R., Brunet, J., Lupu, R., and Menendez, J.A.
(2008). Overexpression of fatty acid synthase gene activates HER1/HER2 tyro-
sine kinase receptors in human breast epithelial cells. Cell Prolif. 41, 59–85.Wang, D., Wang, H., Ning, W., Backlund, M.G., Dey, S.K., and DuBois, R.N.
(2008). Loss of cannabinoid receptor 1 accelerates intestinal tumor growth.
Cancer Res. 68, 6468–6476.
Welch, D.R., Bisi, J.E., Miller, B.E., Conaway, D., Seftor, E.A., Yohem, K.H.,
Gilmore, L.B., Seftor, R.E., Nakajima, M., and Hendrix, M.J. (1991). Character-
ization of a highly invasive and spontaneously metastatic human malignant
melanoma cell line. Int. J. Cancer 47, 227–237.
Wise, D.R., DeBerardinis, R.J., Mancuso, A., Sayed, N., Zhang, X.Y., Pfeiffer,
H.K., Nissim, I., Daikhin, E., Yudkoff, M., McMahon, S.B., et al. (2008). Myc
regulates a transcriptional program that stimulates mitochondrial glutaminoly-
sis and leads to glutamine addiction. Proc. Natl. Acad. Sci. USA 105,
18782–18787.
Yuan, T.L., and Cantley, L.C. (2008). PI3K pathway alterations in cancer:
variations on a theme. Oncogene 27, 5497–5510.
Zechner, R., Strauss, J.G., Haemmerle, G., Lass, A., and Zimmermann, R.
(2005). Lipolysis: pathway under construction. Curr. Opin. Lipidol. 16,
333–340.
Zhao, Q., He, Z., Chen, N., Cho, Y.Y., Zhu, F., Lu, C., Ma, W.Y., Bode, A.M.,
and Dong, Z. (2005). 2-Arachidonoylglycerol stimulates activator protein-1-
dependent transcriptional activity and enhances epidermal growth factor-
induced cell transformation in JB6 P+ cells. J. Biol. Chem. 280, 26735–26742.
Zhou, W., Han, W.F., Landree, L.E., Thupari, J.N., Pinn, M.L., Bililign, T., Kim,
E.K., Vadlamudi, A., Medghalchi, S.M., El Meskini, R., et al. (2007). Fatty acid
synthase inhibition activates AMP-activated protein kinase in SKOV3 human
ovarian cancer cells. Cancer Res. 67, 2964–2971.
Zunder, E.R., Knight, Z.A., Houseman, B.T., Apsel, B., and Shokat, K.M.
(2008). Discovery of drug-resistant and drug-sensitizing mutations in the
oncogenic PI3K isoform p110 alpha. Cancer Cell 14, 180–192.Cell 140, 49–61, January 8, 2010 ª2010 Elsevier Inc. 61
